Our continued global expansion reflects our holistic approach to supporting our customers throughout their clinical development. By investing in both technology and capacity, we are working to provide our partners with tailored early‑stage manufacturing services that enable their molecules to progress successfully from the lab to the clinic.
Dr. Claus Feussner, Senior Vice President of Vetter Development Service
U.S. facilities with strong performance and major expansion efforts
We continue to maintain strong momentum in the United States. Our site in Skokie, Illinois, remains a cornerstone for global biotech partners navigating the complexities of clinical development. Since opening, we have supported more than 140 customers and over 350 compounds. More than 40 % of these customers are start‑ups or small companies with fewer than 50 employees.
Building on this foundation, construction of our new 160,000‑square‑foot facility in Des Plaines, Illinois, is progressing on schedule. With the steel structure nearly completed, interior construction will begin shortly. Once operational in 2029, the site will further expand our U.S. clinical manufacturing capabilities and reinforce our long‑term commitment to growth and patient support.
European site scales for customer demand
Our European clinical manufacturing site in Rankweil, Austria, has also reached a new level of operational maturity to support the increasing complexities of drug product development. To accommodate steadily rising project volumes, we are implementing several infrastructure enhancements designed to increase capacity and streamline production processes for human Investigational Medicinal Products.
These enhancements include the installation of a new weighing room, an additional compounding room within the aseptic production area, and expanded capacity for manual visual inspection. In addition, the site will benefit from new cold‑storage rooms, specialized freezer units for API storage, and an additional incubator chamber to further strengthen microbiological testing capabilities.
By strengthening our capabilities on both sides of the Atlantic, we continue to reinforce our position as a global partner for comprehensive and cGMP‑compliant clinical development and aseptic filling. The close alignment of our European and U.S. clinical sites supports harmonized processes, consistent quality standards, and the flexibility required to meet the evolving needs of customers worldwide.
